Article Details
Retrieved on: 2024-07-23 15:19:20
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
... AstraZeneca (LSE/STO/Nasdaq: AZN) for a preclinical EGFR degrader candidate. Under the terms of the agreement, AstraZeneca will be granted an ...
Article found on: www.prnewswire.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here